Journal of Clinical Endocrinology & Metabolism, Vol 80, 922-926, Copyright © 1995 by Endocrine Society

ARTICLES

Autoimmune endocrine disease induced by recombinant interferon-alpha therapy for chronic active type C hepatitis

A Imagawa, N Itoh, T Hanafusa, Y Oda, M Waguri, J Miyagawa, N Kono, M Kuwajima and Y Matsuzawa
Second Department of Internal Medicine, Osaka University Medical School, Suita, Japan.

To elucidate the role played by interferon-alpha (IFN alpha) in the pathogenesis of autoimmune endocrine disease, we determined the autoantibody status, thyroid function test results, hemoglobin-A1c levels, and clinical symptoms of 58 patients who received IFN alpha for treatment of chronic active type C hepatitis. Each patient was treated for 6 months with a total dose of 391 +/- 140 x 10(6) U (mean +/- SD). Thyroid microsomal and/or thyroglobulin antibodies newly appeared or were increased in titer in 6 patients, 2 of whom developed hypothyroidism during IFN alpha therapy. Neither islet cell antibodies nor insulin-dependent diabetes mellitus developed during IFN alpha therapy, although hemoglobin-A1c levels were increased in 2 patients. One patient became positive for antimitochondrial antibodies, and another patient with preexisting antimitochondrial antibodies also manifested deterioration in liver function test results. Parietal cell antibodies and smooth muscle cell antibodies were the most frequent newly developed antibodies in 7 patients. Adrenal medullary cell antibodies and nuclear antibodies newly developed in 2 and 1 patients, respectively. At least 1 of 8 autoantibodies newly appeared in 19 patients (32.8%) and hypothyroidism developed in 2 patients (3.4%) during IFN alpha therapy. On the other hand, in 19 age- and sex-matched patients who did not receive IFN alpha, no autoantibody appeared, and no autoimmune disease developed during a follow-up period of 3 months. These findings suggest that IFN alpha acts as an immunomodulatory agent, inducing autoantibody production and the development of autoimmune disease in susceptible patients. Special attention should be paid to the development of hypothyroidism during IFN alpha therapy.

This article has been cited by other articles:

				N. Harii, C. J. Lewis, V. Vasko, K. McCall, U. Benavides-Peralta, X. Sun, M. D. Ringel, M. Saji, C. Giuliani, G. Napolitano, et al. Thyrocytes Express a Functional Toll-Like Receptor 3: Overexpression Can Be Induced by Viral Infection and Reversed by Phenylmethimazole and Is Associated with Hashimoto's Autoimmune Thyroiditis Mol. Endocrinol., May 1, 2005; 19(5): 1231 - 1250. [Abstract] [Full Text] [PDF]

				E. J. Bini and S. Mehandru Incidence of Thyroid Dysfunction During Interferon Alfa-2b and Ribavirin Therapy in Men With Chronic Hepatitis C: A Prospective Cohort Study Arch Intern Med, November 22, 2004; 164(21): 2371 - 2376. [Abstract] [Full Text] [PDF]

				C. Carella, G. Mazziotti, G. Amato, L. E. Braverman, and E. Roti Interferon-{alpha}-Related Thyroid Disease: Pathophysiological, Epidemiological, and Clinical Aspects J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3656 - 3661. [Full Text] [PDF]

				A Altintas, Y Alici, M Melikoglu, and A Siva Arthritis during interferon beta-1b treatment in multiple sclerosis Multiple Sclerosis, December 1, 2002; 8(6): 534 - 536. [Abstract] [PDF]

				C. Carella, G. Mazziotti, F. Morisco, G. Manganella, M. Rotondi, C. Tuccillo, F. Sorvillo, N. Caporaso, and G. Amato Long-Term Outcome of Interferon-{{alpha}}-Induced Thyroid Autoimmunity and Prognostic Influence of Thyroid Autoantibody Pattern at the End of Treatment J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 1925 - 1929. [Abstract] [Full Text]

				B Wesche, E Jaeckel, C Trautwein, H Wedemeyer, A Falorni, H Frank, A von zur Muhlen, M-P Manns, and G Brabant Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C Gut, March 1, 2001; 48(3): 378 - 383. [Abstract] [Full Text] [PDF]

				L. Fernandez-Soto, A. Gonzalez, F. Escobar-Jimenez, R. Vazquez, E. Ocete, N. Olea, and J. Salmeron Increased Risk of Autoimmune Thyroid Disease in Hepatitis C vs Hepatitis B Before, During, and After Discontinuing Interferon Therapy Arch Intern Med, July 13, 1998; 158(13): 1445 - 1448. [Abstract] [Full Text]

				S.-C. J. Yeung, A. C. Chiu, R. Vassilopoulou-Sellin, and R. F. Gagel The Endocrine Effects of Nonhormonal Antineoplastic Therapy Endocr. Rev., April 1, 1998; 19(2): 144 - 172. [Abstract] [Full Text]

				C. M. Dayan and G. H. Daniels Chronic Autoimmune Thyroiditis N. Engl. J. Med., July 11, 1996; 335(2): 99 - 107. [Full Text] [PDF]